Allena Pharmaceuticals, Inc.
allenapharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2022 10-Q, filed Aug 15, 2022. Its latest SEC filing is a SEC STAFF ACTION from Jun 12, 2023.
10-Q for Q2 FY2022, filed Aug 15, 2022
The sections below describe the company as of the FY2021 annual report.
What Did They Do?
Develops oral enzyme therapies for rare metabolic and kidney disorders, including a candidate designed to lower uric acid for people with gout and chronic kidney disease.
10-K for FY2021, filed Mar 31, 2022We are a biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients…View ↗
Our product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the…View ↗
We engineered ALLN-346 to degrade urate in the GI tract and, in turn, reduce the urate burden on the kidney and lower the risk of…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2021, filed Mar 31, 2022
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2022, filed Aug 15, 2022
−$8.4MView ↗
- ▼ −40% (Loss)
- vs −$14M in Q2 FY2021
-
Sep 7, 2022
Nasdaq scheduled suspension of trading and delisting
The company withdrew its hearing request after filing for Chapter 11; Nasdaq said trading would be suspended and expected to delist the shares.
Sources
8-K, filed Sep 7, 2022
On September 2, 2022, after considering all strategic alternatives, the Company filed a voluntary petition for relief under the provisions…View ↗
-
Sep 2, 2022
Filed for bankruptcy and terminated CEO and CFO
The company said it would continue operating at a reduced level as a debtor-in-possession.
Sources
8-K, filed Sep 2, 2022
On September 2, 2022, after considering all strategic alternatives, the Company filed a voluntary petition (the “Voluntary Petition”) for…View ↗
Candidate focus
The older report presents an oxalate-treatment candidate as the lead program alongside an urate-treatment candidate; the latest report centers on the urate candidate and says development of the oxalate program ended.
10-K for FY2018, filed Mar 7, 2019 10-K for FY2021, filed Mar 31, 2022
Commercial plans
The older report planned to seek U.S. approval and build a focused sales organization for its oxalate candidate; the latest report says strategic partners may support further development and commercialization of its urate candidate.
10-K for FY2018, filed Mar 7, 2019 10-K for FY2021, filed Mar 31, 2022Commercialize reloxaliase-We have worldwide commercialization and development rights to reloxaliase. We intend to independently pursue…View ↗
We hold worldwide development and commercialization rights to ALLN-346. Provided that we are able to secure adequate funding to continue…View ↗
Who Did They Compete With?
Competes with Horizon Therapeutics, Selecta Biosciences, and Swedish Orphan Biovitrum
10-K for FY2021, filed Mar 31, 2022There are currently three classes of drugs approved to treat hyperuricemia and gout including established classes of xanthine oxidase…View ↗
Loading...
